Clinical Commander

Back to dossier
cardio.stemi.sickle-cell-vaso-occlusion.v1PRODUCTION
cardio.stemi.sickle-cell-vaso-occlusion.v1

STEMI in sickle cell disease (vaso-occlusive / microvascular)

cardiologyacuteadult
Hard-required inputs
0 / 10
Care setting:

Encounter flow

10/12 authored

Canonical 12-phase frame with authored status for this dossier.

Current phase

Frame

Detailed

STEMI/NSTEMI in SCD = often microvascular MINOCA pattern from vaso-occlusion + endothelial dysfunction; route to cardio.stemi.core.v1 reperfusion arc but flag SCD-specific exchange transfusion + hydration + pain control

Inputs
2
Actions
0
Advance rule
Set
Advance when

STEMI confirmed + SCD context elicited

Patient inputs (10)

SCD-related ACS often presents younger than de novo ASCVD; presentations in pregnancy + post-op + dehydration triggers

HbSS most severe; baseline HbS% guides exchange transfusion target (<30%)

Identify reversible triggers — dehydration, infection, pregnancy, post-op, hypoxia, cold exposure

SCD nephropathy common; baseline AKI from VOC/rhabdomyolysis must be assessed before contrast

Standard STEMI criteria; SCD patients may have baseline LVH from chronic anemia

Standard ACS biomarker; in SCD microvascular MI may have modest elevation; serial trending essential

Baseline + acute hemolysis markers; hyperhemolysis screening; informs exchange transfusion urgency

Hypotension may indicate sepsis (functional asplenia → encapsulated organism risk), splenic sequestration, or true cardiogenic compromise

Hypoxia must be corrected aggressively — perpetuates sickling; low threshold for supplemental O2 even at "normal" SpO2 if symptomatic

Emergent cath to exclude obstructive disease; expect MINOCA pattern (non-obstructive); cardiac MRI critical for confirming microvascular MI vs myocarditis vs Takotsubo

* = hard-required. Engine cannot meaningfully run until these are filled.

Severity triggers (4)

4 need judgement
  • informationallife_threateningacute_chest_syndrome_overlap_with_stemi
    New CXR infiltrate + chest pain + hypoxia + fever in SCD patient with concurrent STEMI presentation — acute chest syndrome may be primary or co-morbid driver
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningstroke_risk_during_acs_in_scd
    SCD patient with new neurologic symptoms during ACS workup — stroke risk elevated in SCD baseline + acute illness
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseverevoc_with_troponin_elevation_overlapping_acs
    Vaso-occlusive crisis + troponin elevation — requires differentiation between true ACS, microvascular MI, demand ischemia, and acute chest syndrome
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalsevereexchange_transfusion_bleed_risk_on_anticoagulation
    Need for full-dose anticoagulation post-PCI in patient with concurrent VOC + rhabdomyolysis (elevated bleed risk)
    Trigger could not be auto-evaluated — needs clinician judgement.

Workflow calculators

Run this disease's risk and dosing calculators inline.

RISK_STRATIFICATIONoptionalDrives risk stratification
Loading…

Recommended regimen

SCD STEMI / vaso-occlusion phenotype — adds to parent cardio.stemi.core.v1 reperfusion regimen with SCD-specific exchange + hydration + pain control
axis: scd_stemi_phenotype
Selected axis "SCD STEMI / vaso-occlusion phenotype — adds to parent cardio.stemi.core.v1 reperfusion regimen with SCD-specific exchange + hydration + pain control" by default fallback (first axis)
  • aspirin
    first line
    antiplatelet_cox1
    162-325 mg chewed • PO • load + 81 mg daily
    triggers: stemi_in_scd
    AHA 2025 Class I; same as parent — proceed unless active bleed/hyperhemolysis
    rxcui 243670
  • ticagrelor
    first line
    p2y12_inhibitor
    180 mg load → 90 mg BID • PO • BID × 12 mo default DAPT
    triggers: stemi_pci_planned_in_scd
    PLATO PMID 19717846; cautious if rhabdomyolysis from VOC + bleed risk elevated
    rxcui 1116632
  • heparin
    first line
    anticoagulant_unfractionated
    70-100 U/kg IV bolus — REDUCE if hyperhemolysis or rhabdomyolysis • IV • bolus + infusion
    triggers: stemi_pci_planned_in_scd
    AHA 2025 Class I; titrate cautiously given elevated bleed risk in active VOC
    rxcui 5224
  • automated_red_cell_exchange_transfusion
    first line
    apheresis_procedure
    target HbS <30% post-exchange • IV apheresis • single procedure ± repeat per HbS%
    triggers: scd_stemi_or_acute_chest_syndrome
    NHLBI 2014 + ASH 2020 — automated red cell exchange (not simple transfusion) for severe SCD complications including ACS/MI overlap; reverses microvascular occlusive substrate
  • morphine
    first line
    opioid_analgesic
    0.1-0.15 mg/kg IV q3-4h or PCA • IV/PCA • q3-4h or continuous PCA
    triggers: voc_severe_pain
    NHLBI 2014 + ASH 2020 — opioid pain control essential; PCA preferred; switch to hydromorphone if morphine intolerance
    rxcui 7052
  • hydromorphone
    second line
    opioid_analgesic
    0.015 mg/kg IV q3-4h or PCA • IV/PCA • q3-4h or continuous PCA
    triggers: morphine_intolerance, renal_impairment
    Alternative opioid; preferred in renal impairment vs morphine
    rxcui 3423
  • atorvastatin
    add on
    hmg_coa_reductase_inhibitor
    80 mg PO daily • PO • daily
    triggers: stemi_post_pci
    PROVE-IT extrapolation; SCD endothelial dysfunction may benefit from statin pleiotropic effects
    rxcui 83367
  • carvedilol
    add on
    beta_blocker_alpha_beta
    3.125 mg BID titrate • PO • BID
    triggers: lvef_below_40
    CAPRICORN PMID 11356436
    rxcui 20352
  • hydroxyurea
    comorbidity specific
    antineoplastic_ribonucleotide_reductase_inhibitor
    15 mg/kg PO daily, titrate to MTD • PO • daily
    triggers: scd_baseline_or_post_voc_initiation
    NHLBI 2014 Class I — hydroxyurea for HbSS adults + recurrent VOC; MSH trial Charache PMID 7531569
    rxcui 5552

outpatient playbook — drug actions (1)

  1. 1. continue secondary-prevention + SCD bundle
    rxcui 243670
    ASA 81 + statin + ACEi/ARB if EF <40 + hydroxyurea + adjuncts • PO • as scheduled
    trigger: post-SCD-STEMI
    AHA 2025 + NHLBI 2014 + ASH 2020

Auto-drafted A&P note

outpatient

Subjective

- Possible entry pathways: Known SCD (HbSS, HbSC, HbS-β-thal) presenting with chest pain → STEMI/NSTEMI workup with VOC + ACS overlap consideration; ST-elevation pattern on ECG in SCD patient — emergent cath; expect microvascular pattern more often than obstructive plaque; Vaso-occlusive crisis + chest pain + troponin elevation — overlaps with ACS, acute chest syndrome, microvascular MI.

Objective

- No vitals, labs, or imaging entered for this encounter.

Assessment

**STEMI in sickle cell disease (vaso-occlusive / microvascular)** (cardio.stemi.sickle-cell-vaso-occlusion.v1).
Scope: STEMI/NSTEMI in SCD = often microvascular MINOCA pattern from vaso-occlusion + endothelial dysfunction; route to cardio.stemi.core.v1 reperfusion arc but flag SCD-specific exchange transfusion + hydration + pain control

No severity triggers fired against current inputs.

Plan

Regimen axis: **SCD STEMI / vaso-occlusion phenotype — adds to parent cardio.stemi.core.v1 reperfusion regimen with SCD-specific exchange + hydration + pain control**.
1. aspirin 162-325 mg chewed PO load + 81 mg daily (antiplatelet_cox1, first line) — AHA 2025 Class I; same as parent — proceed unless active bleed/hyperhemolysis
2. ticagrelor 180 mg load → 90 mg BID PO BID × 12 mo default DAPT (p2y12_inhibitor, first line) — PLATO PMID 19717846; cautious if rhabdomyolysis from VOC + bleed risk elevated
3. heparin 70-100 U/kg IV bolus — REDUCE if hyperhemolysis or rhabdomyolysis IV bolus + infusion (anticoagulant_unfractionated, first line) — AHA 2025 Class I; titrate cautiously given elevated bleed risk in active VOC
4. automated_red_cell_exchange_transfusion target HbS <30% post-exchange IV apheresis single procedure ± repeat per HbS% (apheresis_procedure, first line) — NHLBI 2014 + ASH 2020 — automated red cell exchange (not simple transfusion) for severe SCD complications including ACS/MI overlap; reverses microvascular occlusive substrate
5. morphine 0.1-0.15 mg/kg IV q3-4h or PCA IV/PCA q3-4h or continuous PCA (opioid_analgesic, first line) — NHLBI 2014 + ASH 2020 — opioid pain control essential; PCA preferred; switch to hydromorphone if morphine intolerance
6. hydromorphone 0.015 mg/kg IV q3-4h or PCA IV/PCA q3-4h or continuous PCA (opioid_analgesic, second line) — Alternative opioid; preferred in renal impairment vs morphine
7. atorvastatin 80 mg PO daily PO daily (hmg_coa_reductase_inhibitor, add on) — PROVE-IT extrapolation; SCD endothelial dysfunction may benefit from statin pleiotropic effects
8. carvedilol 3.125 mg BID titrate PO BID (beta_blocker_alpha_beta, add on) — CAPRICORN PMID 11356436
9. hydroxyurea 15 mg/kg PO daily, titrate to MTD PO daily (antineoplastic_ribonucleotide_reductase_inhibitor, comorbidity specific) — NHLBI 2014 Class I — hydroxyurea for HbSS adults + recurrent VOC; MSH trial Charache PMID 7531569

Setting playbook (outpatient) — Long-term SCD + cardiology dual surveillance: hydroxyurea MTD maintenance, voxelotor/crizanlizumab/L-glutamine adjuncts as indicated, transcranial Doppler stroke screen, cardiac MRI follow-up, secondary prevention bundle
10. continue secondary-prevention + SCD bundle ASA 81 + statin + ACEi/ARB if EF <40 + hydroxyurea + adjuncts PO as scheduled — post-SCD-STEMI (AHA 2025 + NHLBI 2014 + ASH 2020)

Non-pharmacologic actions:
- SCD clinic continuity
- Stroke screening + bone marrow transplant evaluation if eligible (curative)

AVOID / contraindication checks:
- Full_dose_anticoagulation_caution_in_active_voc_with_rhabdomyolysis (ASH 2020)
- Simple_transfusion_avoid_in_severe_complications_use_exchange (NHLBI 2014)
- Morphine_avoid_in_severe_renal_impairment_egfr_below_30 (use hydromorphone)
- Over_hydration_can_precipitate_acute_chest_syndrome (ASH 2020 — target euvolemia not aggressive bolus)

Monitoring

Regimen monitoring:
- serial hbs percent post exchange target below 30
- serial cbc retic ldh haptoglobin for hemolysis trending
- cxr q12 24h for acute chest syndrome evolution
- opioid sedation score q4h
- renal function q12h for aki from voc and contrast

Setting (outpatient) monitoring:
- Quarterly clinic + annual MRI + lipid

Follow-up plan: Cardiology + hematology dual follow-up; initiate or up-titrate hydroxyurea (NHLBI Class I); consider L-glutamine, voxelotor, crizanlizumab; transcranial Doppler stroke screen (children + repeat in adults); SCD specialty clinic enrollment
- Close-out criterion: chronic SCD therapy + cardiology bundle in place

Monitoring phase: Telemetry; serial CBC + retic + LDH (hemolysis trending); CXR for acute chest syndrome evolution; opioid effect + sedation; renal function trending; HbS% post-exchange

Disposition

Current setting: outpatient — Long-term SCD + cardiology dual surveillance: hydroxyurea MTD maintenance, voxelotor/crizanlizumab/L-glutamine adjuncts as indicated, transcranial Doppler stroke screen, cardiac MRI follow-up, secondary prevention bundle

Disposition criteria:
- Long-term continuation; cross-link to hematology SCD program + cardiology

Escalation triggers (move to higher acuity):
- Recurrent VOC despite triple-therapy → consider transplant evaluation
- New cardiac symptoms → return for eval

Earlier-Return Triggers

Return-precaution thresholds (watch for):
- [LIFE_THREATENING] New CXR infiltrate + chest pain + hypoxia + fever in SCD patient with concurrent STEMI presentation — acute chest syndrome may be primary or co-morbid driver
- [LIFE_THREATENING] SCD patient with new neurologic symptoms during ACS workup — stroke risk elevated in SCD baseline + acute illness
- [SEVERE] Vaso-occlusive crisis + troponin elevation — requires differentiation between true ACS, microvascular MI, demand ischemia, and acute chest syndrome

Citations

- 2025 ACC/AHA ACS Guideline + NHLBI 2014 SCD Expert Panel + ASH 2020 SCD Acute Complications Guideline [PMID:25203083](https://pubmed.ncbi.nlm.nih.gov/25203083/)
- Cited evidence (PMID 32114555) [PMID:32114555](https://pubmed.ncbi.nlm.nih.gov/32114555/)
- Cited evidence (PMID 32058561) [PMID:32058561](https://pubmed.ncbi.nlm.nih.gov/32058561/)
- Cited evidence (PMID 25274294) [PMID:25274294](https://pubmed.ncbi.nlm.nih.gov/25274294/)
- Cited evidence (PMID 29516076) [PMID:29516076](https://pubmed.ncbi.nlm.nih.gov/29516076/)

Last reconciled with current guidelines: 2026-05-15.
References